Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 487,876 |
|
|||||
| News | - | ||||||
| Day High | 8.65 | Low High |
|||||
| Day Low | 8.25 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| ARS Pharmaceuticals Inc | SPRY | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.03 | 0.36% | 8.47 | 16:15:01 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 8.41 | 8.25 | 8.65 | 8.47 | 8.44 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 7,961 | 487,876 | $ 8.42 | $ 4,110,308 | - | 2.55 - 11.27 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:45:39 | 9 | $ 8.47 | USD |
ARS Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 817.37M | - | - | - | -1,503.48 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
ARS Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SPRY Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 9.24 | 9.47 | 8.25 | 8.91 | 600,216 | -0.77 | -8.33% |
| 1 Month | 9.00 | 11.27 | 8.25 | 9.49 | 801,694 | -0.53 | -5.89% |
| 3 Months | 6.58 | 11.27 | 6.13 | 8.73 | 709,828 | 1.89 | 28.72% |
| 6 Months | 3.54 | 11.27 | 3.35 | 6.87 | 600,366 | 4.93 | 139.27% |
| 1 Year | 6.86 | 11.27 | 2.55 | 6.39 | 1,033,375 | 1.61 | 23.47% |
| 3 Years | 5.28 | 11.27 | 2.55 | 6.48 | 791,187 | 3.19 | 60.42% |
| 5 Years | 5.28 | 11.27 | 2.55 | 6.48 | 791,187 | 3.19 | 60.42% |
ARS Pharmaceuticals Description
| ARS Pharmaceuticals Inc is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The company is developing neffy, an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications, and insect bites that could lead to life-threatening anaphylaxis. |
